Author pages are created from data sourced from our academic publisher partnerships and public sources.
Share This Author
Pembrolizumab for the treatment of non-small cell lung cancer
- S. H. Lim, Jong-Mu Sun, S. Lee, J. Ahn, K. Park, M. Ahn
- Expert opinion on biological therapy
- 3 March 2016
ABSTRACT Introduction: Immune checkpoint inhibitors targeting programmed death protein 1 (PD-1) receptor and its ligand, PD-L1, have recently led to significant and durable improvements in the… Expand
Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial.
BACKGROUND Results from clinical trials have established sunitinib as a standard of care for first-line treatment of advanced or metastatic renal-cell carcinoma (RCC); however, many patients,… Expand
Total lesion glycolysis in positron emission tomography is a better predictor of outcome than the International Prognostic Index for patients with diffuse large B cell lymphoma
This study was undertaken to evaluate the prognostic value of quantitative metabolic parameters in [18F]2‐fluoro‐2‐deoxyglucose (FDG)‐positron emission tomography (PET) for diffuse large B cell… Expand
Functional analysis of receptor tyrosine kinase mutations in lung cancer identifies oncogenic extracellular domain mutations of ERBB2
- H. Greulich, B. Kaplan, +25 authors M. Meyerson
- Biology, Medicine
- Proceedings of the National Academy of Sciences
- 20 August 2012
We assessed somatic alleles of six receptor tyrosine kinase genes mutated in lung adenocarcinoma for oncogenic activity. Five of these genes failed to score in transformation assays; however, novel… Expand
Primary pulmonary non-Hodgkin's lymphoma.
BACKGROUND Primary pulmonary non-Hodgkin's lymphoma is a very rare neoplasm. It is represented most commonly by marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT) type.… Expand
An observational study suggesting clinical benefit for adjuvant postoperative chemoradiation in a population of over 500 cases after gastric resection with D2 nodal dissection for adenocarcinoma of…
- S. Kim, D. Lim, +17 authors K. Park
- International journal of radiation oncology…
- 1 December 2005
PURPOSE The role of adjuvant chemoradiotherapy (CRT) in D2-resected gastric-cancer patients has not been defined yet. We investigated the effect of postoperative chemoradiotherapy on the relapse rate… Expand
Mechanisms of Acquired Resistance to AZD9291: A Mutation-Selective, Irreversible EGFR Inhibitor
- T. Kim, Ahnah Song, +7 authors D. Heo
- Journal of thoracic oncology : official…
- 1 December 2015
Introduction: AZD9291, a third-generation and mutation-selective epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), is active against patients with EGFRT790M-mutant… Expand
Pembrolizumab versus chemotherapy as second-line therapy for advanced esophageal cancer: Phase III KEYNOTE-181 study.
2Background: Patients with advanced esophageal cancer after first-line chemotherapy (chemo) have a poor prognosis and limited treatment options. We present results of the phase 3 KEYNOTE-181 study ...
Safety and Antitumor Activity of Pembrolizumab in Patients With Programmed Death-Ligand 1-Positive Nasopharyngeal Carcinoma: Results of the KEYNOTE-028 Study.
- Chiun Hsu, S. Lee, +10 authors A. Hansen
- Journal of clinical oncology : official journal…
- 24 August 2017
Purpose To establish the safety profile and antitumor activity of the anti-programmed death 1 receptor monoclonal antibody, pembrolizumab, in patients with recurrent or metastatic nasopharyngeal… Expand
ERCC1 expression by immunohistochemistry and EGFR mutations in resected non-small cell lung cancer.
Expression of excision repair cross-complementation group 1 (ERCC1) is important for resistance to platinum agents. Mutations of epidermal growth factor receptor (EGFR) are related to the… Expand